Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pet Pharm Biotech CoROCO:7762 +0.20%19 OCF Yield % is 1.19 as of Jul. 21, 2026, which is 6% below its 10-year median of 1.26. GuruFocus rates ROCO:7762 with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Pet Pharm Biotech Co ranks worse than 64.18% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Pet Pharm Biotech Co OCF Yield % Related Terms
Pet Pharm Biotech Co OCF Yield % Historical Data
* Premium members only.
The historical data trend for Pet Pharm Biotech Co's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7762 vs LLY, JNJ, ABBV: OCF Yield % Comparison
For the Drug Manufacturers - General subindustry, Pet Pharm Biotech Co's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pet Pharm Biotech Co OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pet Pharm Biotech Co's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Pet Pharm Biotech Co's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pet Pharm Biotech Co (ROCO:7762) has a OCF Yield % of 1.19 as of Jul. 21, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Pet Pharm Biotech Co and its competitors. This is near median its historical median of 1.26. Over the past decade, Pet Pharm Biotech Co's OCF Yield % has ranged from 0.82 to 2.36. According to the industry distribution chart, Pet Pharm Biotech Co ranks #645 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 64.2%.
Is Pet Pharm Biotech Co's OCF Yield % too high?
Pet Pharm Biotech Co's current OCF Yield % of 1.19 is near median its 10-year median of 1.26. Over the past 10 years, this metric has ranged from a low of 0.82 to a high of 2.36. The Drug Manufacturers industry median OCF Yield % is 3.62. Pet Pharm Biotech Co's value of 1.19 is 67.1% below this industry median. Based on the distribution chart, Pet Pharm Biotech Co ranks #645 out of 1005 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Pet Pharm Biotech Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's OCF Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Pet Pharm Biotech Co ranks #645 out of 1005 companies for OCF Yield %. This places Pet Pharm Biotech Co in the lower half of its industry. The industry median OCF Yield % is 3.62. Pet Pharm Biotech Co's value of 1.19 is 67.1% below this benchmark. Historically, Pet Pharm Biotech Co's own OCF Yield % has ranged from 0.82 to 2.36 over the past decade. While the company's 10-year median is 1.26 vs. the industry median of 3.62, Pet Pharm Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.62, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pet Pharm Biotech Co's current OCF Yield % of 1.19 is 67.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Pet Pharm Biotech Co and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pet Pharm Biotech Co's current OCF Yield % is 1.19, which is near median its own 10-year median of 1.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current OCF Yield % of 1.19. The current OCF Yield % is 1.19, which is near median its 10-year median of 1.26 and 67.1% below the Drug Manufacturers industry median of 3.62. Pet Pharm Biotech Co's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current OCF Yield % is 1.19 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
19GF Score
Get the complete analysis for ROCO:7762
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7762 has been successfully added to your 
